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CORRESPONDENCE
Advice to health professionals: Use of 
lignocaine as a diluent to reduce the 
pain associated with the administration 
of benzathine penicillin G
To the Editor: Rheumatic heart disease (RHD) is a consequence of 
untreated group A beta-haemolytic streptococcal pharyngitis in a 
susceptible individual who is likely to live under social conditions 
of poverty.[1] There are over 30 million people with the disease, 
which is associated with over 300 000 deaths per year worldwide. [2] 
In Mozambique and South Africa, RHD is estimated to affect 
20 - 30/1 000 asymptomatic schoolchildren.[3,4] Intramuscular peni-
cillin is more effective than oral penicillin in the secondary preven tion 
of acute rheumatic fever (ARF), and is highly effective for the primary 
prevention of ARF in children and young adults with pharyngitis.[5,6] 
Intramuscular benzathine penicillin G (BPG) is therefore a first-line 
drug for primary and secondary prevention of ARF and RHD.[5,7]
Pain is one of the major problems when intramuscular BPG is 
given. With this comes fear of the next injection, which is one of the 
barriers to the primary and secondary prophylaxis of ARF.[8] There 
is therefore a need to identify effective methods to reduce the pain 
associated with BPG injection, and to increase adherence to primary 
and secondary prevention measures for ARF. One of these measures 
is to use lignocaine (lidocaine) as a diluent of BPG for intramuscular 
injection. Lignocaine hydrochloride is a local anaesthetic agent 
which, if added to BPG, reduces the pain of injection and in the 
first 24 hours after injection, while not significantly affecting serum 
penicillin concentrations.[7,9] Its effectiveness can be increased by 
using a vibrating device with a cold pack.[10]
A randomised double-blind, crossover trial was carried out in 18 
children aged 11 - 19 years who required prophylactic treatment 
for rheumatic fever.[9] The children were randomly divided into two 
groups: one received an injection of BPG diluted with 3.2 mL of 
sterile water, followed 1 month later by an injection of BPG diluted 
in lignocaine hydrochloride 1%, and the second group received the 
same regimen in the reverse order. Serum penicillin concentrations 
and subjective pain sensation were determined after each injection. 
Peak serum penicillin concentrations at 24 hours after injection 
were similar for both preparations, as were the other serum values 
measured throughout the month. The pain score immediately after 
the injection was significantly lower with the lignocaine than with the 
sterile water dilution. The data support our recommendation for the 
use of lignocaine hydrochloride 1% as a diluent for BPG.[7,11]
We call upon all health professionals who administer intramuscular 
BPG on a regular basis to seriously consider using 1% lignocaine 
hydrochloride as a diluent instead of sterile water in order to mini-
mise the pain of injection and help to improve adherence to the 
regimen for secondary prevention of a chronic disease like RHD.
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